Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization

Cancer Biother Radiopharm. 2016 Mar;31(2):65-9. doi: 10.1089/cbr.2015.1905.

Abstract

Sorafenib has improved the median overall survival of unresectable or otherwise untreatable hepatocellular carcinoma (HCC) of ∼3 months, compared to supportive cares. Complete response, although rare, has been reported. The authors reported herein a case of complete biochemical and radiological remission of advanced unresectable HCC with lymph node metastasis and tumoral portal vein thrombosis treated by 5 months therapy with sorafenib followed by adjuvant Yttrium-90 radioembolization. At 12 months follow-up, there is no evidence of HCC recurrence.

Keywords: Yttrium-90; advanced hepatocellular carcinoma; radioembolization; sorafenib.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Hepatocellular / metabolism
  • Carcinoma, Hepatocellular / secondary
  • Carcinoma, Hepatocellular / therapy*
  • Chemoradiotherapy
  • Embolization, Therapeutic*
  • Female
  • Humans
  • Liver Neoplasms / metabolism
  • Liver Neoplasms / pathology
  • Liver Neoplasms / therapy*
  • Lymphatic Metastasis
  • Middle Aged
  • Neoplasm Staging
  • Niacinamide / analogs & derivatives*
  • Niacinamide / therapeutic use
  • Phenylurea Compounds / therapeutic use*
  • Portal Vein / drug effects
  • Portal Vein / pathology
  • Portal Vein / radiation effects
  • Radiopharmaceuticals / therapeutic use*
  • Radiotherapy, Adjuvant
  • Remission Induction
  • Sorafenib
  • Thrombosis / metabolism
  • Thrombosis / pathology
  • Thrombosis / therapy*
  • Treatment Outcome
  • Yttrium Radioisotopes / therapeutic use*

Substances

  • Antineoplastic Agents
  • Phenylurea Compounds
  • Radiopharmaceuticals
  • Yttrium Radioisotopes
  • Niacinamide
  • Sorafenib